Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?
- PMID: 36426405
- DOI: 10.1093/eurheartj/ehac680
Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?
Conflict of interest statement
Conflicts of interest: A.M. reports personal fees from Orion, Roche, MSD, Adrenomed, and Fire 1, and grants and personal fees from 4TEEN4, Abbott Diagnostic, Roche Diagnostics, Corteria, S-Form Pharma, and Sphyngotec. A.C.S. reports personal fees from Bayer, MSD, Astra Zeneca, Sanofi, Vifor, Boehringer Ingelheim, and Abbott. P.C.C. reports personal fees from Abbott and Roche.
Comment on
-
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.Eur Heart J. 2023 Jan 1;44(1):41-50. doi: 10.1093/eurheartj/ehac530. Eur Heart J. 2023. PMID: 36254693 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical